The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. [electronic resource]
Producer: 20140708Description: 134 p. digitalISSN:- 1476-4598
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Breast Neoplasms -- drug therapy
- Cell Line, Tumor
- Cyclin-Dependent Kinase Inhibitor p27 -- metabolism
- Drug Resistance, Neoplasm
- Drug Synergism
- Enzyme Activation
- Female
- G1 Phase Cell Cycle Checkpoints -- drug effects
- Humans
- Mice
- Mice, Nude
- Proto-Oncogene Proteins c-akt -- metabolism
- Receptor, ErbB-3 -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Trastuzumab
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.